Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Open access plan is no academic spring

19 July 2012

The government argues that "gold" open access will give us a competitive economic advantage. It will not. The approach as it stands will increase the cost of research but, without reciprocal international agreement, will likely offer a competitive advantage to those who do not invest in UK research.

Professor Stephen Caddick
Vice-provost (enterprise), University College London

Read the full article at www.guardian.co.uk